news roundup

Removing the Risks from Adaptive Pathways: Planning for the Possible?

Peter O’Donnell weighs the varying views in Europe on the risks of going the adaptive pathways route for drug approval.

Collaboration and Transparency Key to More Effective Clinical Research

Jill Wechsler details the two chief reasons why clinical trial quality and efficiency has improved in recent years.

Europe Adds More Voices to Orphan Drug Push

Rare disease interests in Europe add more voices to push for greater backing of research incentives, infrastructure.

How Social Media is Transforming Pharma and Healthcare

Outlining the growing attention and pursuits around social media in adverse event reporting and advancing patient-centric initiatives in clinical trials.

Articles

Optimal Strategies for Compliance with EMA Policy 0070 on the External Publication of Clinical Data

With the EU’s new General Data Protection Regulation coming into force in May this year, the impetus for life sciences firms to cement their data management strategies has increased.

Millennials and their Impact on Clinical Research

The importance of examining this generation's influence on the clinical trial value chain.

Oncology

Master Protocols in Oncology: A Review of the Landscape

With technology’s increasing ability to gather and analyze previously unmanageable data sets, and medicine’s forays into genomics and targeted therapies, the time of the master protocol may be at hand.

Ask the editor

Lisa Henderson
Editor in Chief
Lisa.Henderson@ubm.com